StratDeck

Two stocks in Healthcare

Novo Nordisk A/S vs UCB: profit, growth, debt and price compared

UCB is stronger on 4 of 7 figures: sales growth, debt, analysts' view and price trend. Novo Nordisk A/S is stronger on 3: profit margin, price for its expected profit and dividend.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Novo Nordisk A/S and UCB side by side
Novo Nordisk A/SNOVO-B.COUCBUCB.BR
Net marginStronger: 33.9%25.7%
Revenue growth, past year+5.60%Stronger: +22.50%
Debt to equity61.7%Stronger: 30.8%
Forward P/EStronger: 12.0×19.1×
Dividend yieldStronger: 4.25%0.51%
AnalystsHold · 24Stronger: Buy · 19
From its 200-day average−7.0%Stronger: +19.9%

Share price over the past year

  • Novo Nordisk A/S−5.4%
  • UCB+20.8%

24 Nov 202518 Nov 2026

Novo Nordisk A/S or UCB: which is stronger?

  • NOVO-B.CO

    Which is more profitable?

    Novo Nordisk A/S keeps more of each sale as profit: 33.9% against 25.7%.

  • UCB.BR

    Which is growing its sales faster?

    UCB is growing its sales faster: +22.50% over the past year, against +5.60%.

  • UCB.BR

    Which has borrowed less?

    UCB has borrowed less: its debt is 30.8% of what its shareholders own, against 61.7% for Novo Nordisk A/S.

  • NOVO-B.CO

    Which costs less for the profit it is expected to make?

    Novo Nordisk A/S costs less for the profit it is expected to make: 12.0× its forward earnings, against 19.1×.

  • NOVO-B.CO

    Which pays more in dividends?

    Novo Nordisk A/S pays more back in dividends for what a share costs: 4.25% a year, against 0.51%.

  • UCB.BR

    Which do analysts rate higher?

    Analysts are warmer on UCB: Buy, against Hold for Novo Nordisk A/S.

  • UCB.BR

    Which is in the stronger price trend?

    UCB's price is in the stronger trend: 19.9% above its 200-day average, against 7.0% below.

What each company does

NOVO-B.CONovo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Reports results on 3 February 2027

UCB.BRUCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

Reports results on 25 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.